Get started

Pharmastocks

Axsome Therapeutics building momentum Axsome Therapeutics Inc (AXSM) I have been in this spot trade since $50.77. We are now at $72.93. I have much higher targets as you can see from the chart. This is a long term trade looking to hold for 12 – 24 months however feel that something is going to happen within 6 – 12 months based on the chart. - Forming pennant on chart and RSI. Potential for breakout. - Steadily increasing OBV (On Balance Volume) demonstrating continued interested in the trade. - Stochastic Momentum indicator (not included on chart is driving upwards on the weekly). - You can see the orange boxes which act as accumulation zones with double bottoms before the larger move occurs. - We are above the 200 week and using it as support and we are above the 200 day also using it as support so we have limited downside with strong support. This purchase has been helped me recognized that Pharma appear to companies perform much better when the general market is in decline. They appear to be inverse risk on but also make small advances during risk on periods. It’s a market that I am becoming increasingly interested in as a diversifier and value lock. Obviously this is a smaller pharma company with higher risk in the trade, however if I was Regeneron or Johnson and Johnson and I see Axsome’s patents, drug offerings and the general population they are targeting with depression, Alzheimer’s and fibromyalgia, seems like a no brainer to buy them out. Fundamentals: AXSM are a Small Bio-Pharma company with market cap of $3.17 Billon. In August 2022 Auvelity Anti-Depressants was FDA approved & is the only rapid-acting oral medicine for MDD with labelling describing statistically significant antidepressant efficacy by one week. AXSM received Breakthrough Therapy designation from the FDA for an Alzheimer's disease drug development and are at the NDA phase for developing a drug for acute treatment of migraine. AXSM are also developing a treatment for narcolepsy and separately for fibromyalgia. All in, AXSM's offerings are building momentum. They have developed the fastest acting anti-depressant drug and are bringing it to market, and have a four other drugs in development, all of which have a large patient base. The company would be ripe for a buyout.
NASDAQ:AXSMLong
by PukaCharts
ALKEM LAB BULLSIH PATTERN _Daily Timeframe_NSE:ALKEM Stock is consolidating between 3350 to 3450 approximately a month. Price 3350 is holding as good support. Currently we can see there is a morning star pattern(Bullish Pattern) at support which is a sign of strength. We can go long at these levels and keep SL below swing. The stock should not open gap down on 28th June. Following to this check 1hr time frame we can see there is a reverse head and shoulder although the Shoulder length is a bit low compare to usual H&S. This is a good opportunity for positional traders stock has potential to go 3600 in upcoming weeks. Keep eye, Thank you. This is only for educational purpose, please manage your risk accordingly.
NSE:ALKEMLong
by Rushikesh_09
Merck: Water slide 🛝The pool-season is about to start, and Merck has already secured its place on the water slide, which should take it further downwards below the support at $110.66. However, there is still a 35% chance that the share might catch a bubbling fountain which could push it above the resistance at $119.65. In that case, we would expect Merck to develop a new top in the form of wave alt.B in green in the green zone between $119.87 and $123.79 first before turning downwards again.
NYSE:MRK
by MarketIntel
VRPX Biotechnology Penny Stock Post EarningsVRPX was on a downtrend from mid-February into a reversal the beginning of May. VRPX beat earnings up still has no cash flow which is very common in this subsector. VRPX is priced on the potential of future earnings. The short and long-moving averages ratio shows bullish momentum also shows strength with an upper Bollinger Band "walk". Price has climbed over the POC line so it is higher than the mean of the share price traded for the duration of the volume profile. I see this as a risky long setup expectant of a 40% profit based on the target of the YTD high in February.
NASDAQ:VRPXLong
by AwesomeAvani
Technical analysis of AbbVie #ABBVHey traders, My weekly trade idea. The daily price is forming a textbook Cup&Handle formation. After the consolidation in the handle phase, the price is ready to go higher. The momentum will push the price and in my opinion, it is headed to test the all-time high in the 180$ area. The Relative Strength Index broke above its trend line and is moving upward to push the price. Furthermore, when we plot different standard deviations and volume profile, it becomes clear that there is a lot of support and volume right below current price levels! I would love to hear your thoughts as well. Cheers
NYSE:ABBVLong
by RickHardyPro
3
JNJ Buy Long on StrengthJNJ fundamentally is a cross between Big Pharm and Consumer Staples Recent Earnings were solid not spectacular but the latter is not expected here. Technically, JNJ climbs higher without much volatility, At the moment it is rising in a small cycle within the supertrend. Strength is increasing and some bearish momentum is exhausting. This is a low-beta stock and it does not react much to the larger broad market. I see this as a good time for a LEAP option for early 2024 at a strike 15% above the current price.
NYSE:JNJLong
by AwesomeAvani
Accumulating PFE from $46.00 - $47.50 This is one of the stocks I hold indefinitely for dividends. we're at the bottom of our current channel and a double bottom is forming in a major area of support. In my previous post I stated my accumulation sections are in the lower end of the channel, so this is prime real estate to enter. Momentum downwards has come to a halt and I believe we will retest the center channel line from this point. I am diversifying a portion of profits I made from the last 2 trade set ups I've posted into PFE. A fundamentally sound entity in our current market economy. I'm sure you could assume why.
NYSE:PFELong
by WatsonsView
SOLARA ACTIVE PHARMA, AT A HUGE DISCOUNT!!i have marked the time of corona crash(2019), with a circle, this stock had not broken its support during a crash too, that means its a stable stock. it has a good fundamentals, due to heavy corrections from past year, this stock had corrected a lot. i have drawn a 5 wave pattern, and this stock will now stock its bull rally, as markets for large caps have corrected, and now its time for mid and small caps to get its bull run. (link provided below). the stock has corrected till its IPO PRICE(when it touched its bottom). this stock has a good future, invest for long term
NSE:SOLARALong
by raghavchoudhary2016
3
GlenmarkHello and welcome to this analysis Glenmark after consolidating near its monthly support attempted a fresh upmove from 350 to 400, Post that it has made a sideways corrective forming a Bullish Harmonic ABCD. The current reversal from 375 could be a higher low of the new uptrend in it and it could rally till 410-425-450 as long as it does not breach 374. Confirmation if it sustains above 390. Good risk reward set up scenario of a higher low formation which could lead to a higher high thereon till its falling trendline
NSE:GLENMARKLong
by Dinesh_C_Nagpal